Menu
← Oncology Approval Tracker
FDA DECISION ·
Lazcluze + Rybrevant
lazertinib with amivantamab-vmjw · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line use with amivantamab for adults with locally advanced or metastatic non-small cell lung cancer and an FDA test-confirmed EGFR exon 19 deletion or exon 21 L858R substitution.
LAMPGEN ANALYSIS
Why it matters
The lazertinib combination adds a first-line targeted regimen for common EGFR variants without a chemotherapy backbone.
What research teams should watch
Coordinate oral supply and infusion appointments, and check the label's venous thromboembolism prophylaxis instructions at initiation.
PRIMARY RECORDS